Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
79 hedge funds and large institutions have $219M invested in Concert Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 14 closing their positions.
169% more call options, than puts
Call options by funds: $592K | Put options by funds: $220K
29% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 21
12% more capital invested
Capital invested by funds: $195M → $219M (+$24.3M)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding
Funds holding: 79 → 79 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$18.6M |
| 2 |
SM
Senvest Management
New York
|
+$3.75M |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$2.87M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.33M |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.68M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$5.09M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.28M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.48M |
| 5 |
SAM
Senzar Asset Management
New York
|
-$1.11M |
CNCE Hedge Fund Activity: Q3 2017 in Review
79 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2017, worth a combined $219M — up 12% from $195M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CNCE positions and 14 closed out — a net gain of 1 holder — while 27 added to existing stakes and 21 trimmed.
The largest buyer was BVF Inc, adding an estimated $18.6M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $6.68M sold.
- 79 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $219M of Concert Pharmaceuticals, Inc. stock for Q3 2017, up 12% quarter-over-quarter.
- 15 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2017 and 14 closed out, a net change of +1 holder.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2017 was BVF Inc, an estimated $18.6M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2017 was Adage Capital Partners, an estimated $6.68M sold.
Based on aggregated 13F filings for Q3 2017.